期刊文献+

同步放化疗治疗Ⅲ期非小细胞肺癌临床分析

下载PDF
导出
摘要 目的探讨Ⅲ期非小细胞肺癌应用同步放化疗综合治疗临床疗效。方法回顾分析本科2005年1月至2008年12月运用综合治疗Ⅲ期非小细胞肺癌45例患者的临床资料。结果放疗结束后,CR、PR、SD、PD率分别为10%,68%,12%,10%。本组15例患者接受2~4个周期后续巩固化疗,余未接受巩固化疗。本组患者1、2、3年生存率分别为62%,32%、15%。本组不良反映较轻,患者可以耐受。结论同步放化疗对不能手术切除的Ⅲ期非小细胞肺癌患者有较好的疗效,且毒副反应小,延长生存期,而且治疗方法安全,患者可以耐受,是目前不能手术切除的Ⅲ期非小细胞肺癌的一种较理想的综合治疗模式,值得临床应用。
作者 马琦
出处 《中国实用医药》 2009年第30期105-106,共2页 China Practical Medicine
  • 相关文献

参考文献5

二级参考文献25

  • 1傅小龙,将国梁,王丽娟,钱浩,傅深,叶明,赵森.局部控制在非小细胞肺癌非手术治疗中意义的探讨[J].上海医学,1996,19(10):559-562. 被引量:20
  • 2[1]Winton T, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage Ⅰ B and Ⅱ non-small cell lung cancer (NSCLC) Intergroup JBR. 10 [C]. Proc Am Soc Clin Oncol, 2004, 23 ( suppl ): 7018a.
  • 3[2]Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ⅰ B non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB)Protocol 9633 [C]. Proc Am Soc Clin Oncol, 2004, 23(suppl):7019a.
  • 4[4]Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer:reappraisal with a rmeta-analysis of randomized controlled trials [J]. J Clin Oncol, 2004, 22(19):3860-3867.
  • 5[5]Zojwalla NJ, Raftopoulos H, Gralla RJ. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients [C]. Proc Am Soc Clin Oncol, 2004, 23:7068a.
  • 6[6]Onishi H, Nagata Y, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ non-small cell lung carcinoma:clinical outcomes in 273 cases of a Japanese multi-institutional study [C]. Proc Am Soc Clin Oncol, 2004, 23:7003a.
  • 7[7]Vokes E, Herndon J, Kelly M, et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT)versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer(NSCLC) :Initial analysis of a randomized phase Ⅲ trial [C]. Proc Am Soc Clin Oncol, 2004, 23:7005a.
  • 8Komaki R,Int J Radiat Oncol Biol Phys,1995年,31卷,807页
  • 9Zanelli GD,Quaia M,Robieux I,et al. Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and phamacokinetic calculations. Eur J Cancer, 1997, 33:486-492.
  • 10Tishler RB, Schiff PB, Geard CR , et al . Taxol: a novel radiation sensitiser. Int J Radiat Oncol Biol Phys , 1992,22:613-617.

共引文献147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部